Organogenesis Holdings Inc. provided earnings guidance for the year ending December 31, 2022. For the year ending December 31, 2022, the Company expects net revenue of between $485 million and $515 million, representing an increase of approximately 4% to 10% year-over-year, and 6% to 13% on an adjusted basis3, as compared to net revenue of $468.1 million for the year ended December 31, 2021. Net income of between $56.5 million and $71.5 million and adjusted net income of between $60.2 million and $75.2 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.82 USD | +1.81% | -5.05% | -31.05% |
13/05 | Morgan Stanley Lowers Price Target on Organogenesis Holdings to $3 From $3.50, Keeps Equalweight Rating | MT |
10/05 | Health Care Edges Higher Amid Rotation to Utilities - Health Care Roundup | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.05% | 37Cr | |
+64.23% | 6.26TCr | |
-2.31% | 4.12TCr | |
+44.36% | 4.03TCr | |
-8.29% | 2.79TCr | |
+11.97% | 2.62TCr | |
-21.16% | 1.91TCr | |
+7.54% | 1.31TCr | |
+27.17% | 1.21TCr | |
+25.72% | 1.23TCr |
- Stock Market
- Equities
- ORGO Stock
- News Organogenesis Holdings Inc.
- Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2022